About MDimune

MDimune develops a smart drug delivery platform, BioDrone™, utilizing cell-derived vesicles to transport therapeutics directly to targeted areas within the body. This technology addresses the challenge of inefficient drug delivery, enhancing the efficacy of treatments for cancer and central nervous system disorders.

```xml <problem> Current drug delivery methods often lack precision, resulting in systemic exposure and limited efficacy, particularly in treating cancers and central nervous system disorders. This inefficiency necessitates higher drug dosages, leading to increased toxicity and reduced therapeutic benefits for patients. </problem> <solution> MDimune has developed BioDrone™, a smart drug delivery platform based on cell-derived vesicles, designed to enhance targeted drug delivery within the body. This technology utilizes vesicles to transport therapeutic payloads directly to specific areas, improving treatment efficacy while minimizing off-target effects. By precisely delivering drugs to the intended site of action, BioDrone™ aims to reduce the required dosage, decrease systemic toxicity, and improve overall patient outcomes. The platform is applicable to a range of therapeutics, including gene therapies (mRNA, siRNA, miRNA), and is being developed for anti-cancer and central nervous system applications, including rare diseases. </solution> <features> - Cell-derived vesicles for targeted drug delivery - Customizable vesicle surface for enhanced targeting of specific tissues or cells - Compatibility with various therapeutic payloads, including small molecules, proteins, and nucleic acids - Scalable manufacturing process for producing clinical-grade BioDrone™ products - Potential for improved drug efficacy and reduced systemic toxicity compared to conventional drug delivery methods - Applications in oncology, neurology, and gene therapy </features> <target_audience> The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing targeted therapies for cancer, central nervous system disorders, and rare diseases. </target_audience> ```

What does MDimune do?

Where is MDimune located?

MDimune is based in Göd, South Korea.

When was MDimune founded?

MDimune was founded in 2015.

How much funding has MDimune raised?

MDimune has raised 8820000.

Location

Göd, South Korea

Founded

2015

Funding

8820000

Employees

10 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

MDimune

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

mdimune.com 100+

Crunchbase

Founded 2015 – Göd, South Korea

Funding

Estimated Funding

$5M+

Team (10+)

No team information available.

Company Description

Problem

Current drug delivery methods often lack precision, resulting in systemic exposure and limited efficacy, particularly in treating cancers and central nervous system disorders. This inefficiency necessitates higher drug dosages, leading to increased toxicity and reduced therapeutic benefits for patients.

Solution

MDimune has developed BioDrone™, a smart drug delivery platform based on cell-derived vesicles, designed to enhance targeted drug delivery within the body. This technology utilizes vesicles to transport therapeutic payloads directly to specific areas, improving treatment efficacy while minimizing off-target effects. By precisely delivering drugs to the intended site of action, BioDrone™ aims to reduce the required dosage, decrease systemic toxicity, and improve overall patient outcomes. The platform is applicable to a range of therapeutics, including gene therapies (mRNA, siRNA, miRNA), and is being developed for anti-cancer and central nervous system applications, including rare diseases.

Features

Cell-derived vesicles for targeted drug delivery

Customizable vesicle surface for enhanced targeting of specific tissues or cells

Compatibility with various therapeutic payloads, including small molecules, proteins, and nucleic acids

Scalable manufacturing process for producing clinical-grade BioDrone™ products

Potential for improved drug efficacy and reduced systemic toxicity compared to conventional drug delivery methods

Applications in oncology, neurology, and gene therapy

Target Audience

The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing targeted therapies for cancer, central nervous system disorders, and rare diseases.